NeuroDex research library
ALS and frontotemporal dementia: TDP-43 biomarker library
TDP-43 pathology is found in most ALS cases, in a large share of frontotemporal dementia and as a co-pathology in Alzheimer’s-spectrum disease. NfL tracks neuronal injury but not TDP-43 biology. These articles cover what TDP-43 is, how it can be measured from blood and how it can support enrollment, target engagement and endpoints.
Start here
Amyotrophic Lateral Sclerosis (ALS)Explore the complexities of ALS and gain insights into its effects on individuals and families in our detailed guide on NeuroDex.Frontotemporal DementiaExplore essential resources on Frontotemporal Dementia at NeuroDex for a comprehensive overview of this complex condition.TDP-43 in ALS & Neurodegeneration: Key InsightsExplore TDP-43’s role in ALS and beyond, its pathology, biomarker challenges, and how neuron-derived EVs are shaping future therapies.TDP-43 ProteinopathyDiscover the impact of TDP-43 Proteinopathy on ALS and neurological disorders in our latest NeuroDex blog post.
TDP-43 from blood
TDP-43 Measurement: Why Blood-Based Detection Has Been So Hard — and How That’s ChangingExplore how NeuroDex’s ExoSORT™ platform enhances neuron-specific TDP-43 detection in ALS for improved treatment insights.TDP-43 in Blood: Proving Target EngagementHow a sponsor developing a TDP-43-targeting therapy can confirm target engagement in people by measuring neuron-derived TDP-43 in blood samples.TDP-43-High Enrichment: A Stratification Model for ALS TrialsWhy NfL falls short for TDP-43-targeting ALS trials, and what a mechanism-specific enrichment model requires for patient stratification.TDP-43 Biomarkers: Why the Next Decade of Neurodegeneration Research Will Focus on TDP-43TDP-43 biomarkers are transforming ALS, FTD, Alzheimer’s disease, and LATE research. Explore the future of neurodegenerative disease detection.
ALS trials and endpoints
Three Gates Between an ALS Biomarker and a Trial EndpointHow does an ALS biomarker become a trial endpoint? The three evidence gates: analytical validation, pharmacodynamic use and qualification.The ALS Clinical Trials Landscape in 2026A 2026 guide to ALS clinical trials: the drug pipeline, staging systems, NfL, and why TDP-43 is the measurement gap trial sponsors still need to…The Role of Biomarkers in ALS Diagnosis & MonitoringExplore how biomarkers improve ALS diagnosis, track progression, and enhance clinical trials with emerging neuron-specific detection methods.ALS Drug Development: A Comparative Analysis of Oral, Antioxidant, & Gene-Targeted ApproachesDiscover how oral medications, antioxidants, and gene therapies are shaping the future of ALS treatment through biomarkers and innovation.Exploring Today’s ALS Treatment Options & Emerging ResearchExplore today’s FDA-approved ALS treatments, multidisciplinary care, and emerging research in gene therapies, stem cells, and biomarkers.
NeuroDex research
NeuroDex ExoSORT™ Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALSExplore how NeuroDex ExoSORT™ measures TDP-43 in ALS, enhancing understanding of treatment responsiveness and neurological biomarkers.NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS ResearchNeuroDex has been selected for a Target ALS Biomarker Consortia Grant to advance blood-based biomarkers for ALS diagnosis and research.NeuroDex 2025: Advancing ALS Biomarker Discovery for Better OutcomesDiscover how NeuroDex 2025 is Advancing ALS Biomarker research by targeting TDP-43 for early detection and improved patient outcomes in ALS.

